Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers
Source abstract
Abstract
The epidermal growth factor receptor (EGFR) is vital for many different types of cancer. Nimotuzumab (NmAb), an anti-EGFR monoclonal antibody (mAb), is used against some of EGFR-overexpressed cancers in various countries. It targets malignant cells and is internalized via receptor-mediated endocytosis. We hypothesized that mAb-nanoparticle conjugation would provide an enhanced therapeutic efficacy, and hence we conjugated NmAb with 27 nm spherical gold nanoparticles (AuNPs) to form AuNP-NmAb nanoconjugates. Using biophysical and spectroscopic methods, including ultraviolet-visible spectroscopy (UV-Vis), transmission electron microscopy (TEM), dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and Fourier-transform infrared spectroscopy (FTIR), the AuNP-NmAb complex was characterized. Furthermore, in vitro studies were performed using a medium-level EGFR-expressing skin cancer cell (A431, EGFRmedium) and low-level EGFR-expressing lung cancer cell (A549, EGFRlow) to evaluate anti-tumor and cellular uptake efficiency via MTT assay and single-particle inductively coupled plasma mass spectrometry (spICP-MS), respectively. In comparison to NmAb monotherapy, the AuNP-NmAb treatment drastically reduced cancer cell survivability: for A431 cells, the IC50 value of AuNP-NmAb conjugate was 142.7 µg/mL, while the IC50 value of free NmAb was 561.3 µg/mL. For A549 cells, the IC50 value of the AuNP-NmAb conjugate was 163.6 µg/mL, while the IC50 value of free NmAb was 1,082.0 µg/mL. Therefore, this study highlights the unique therapeutic potential of AuNP-NmAb in EGFR+ cancers and shows the potential to develop other mAb nanoparticle complexes for a superior therapeutic efficacy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Immunotherapy and Immune Responses · Advanced Biosensing Techniques and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia
References (55)
Show source-provided references
1. Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging10.1021/acs.analchem.5b02572 ↗
2. Wee, P., and Wang, Z. (2017). Epidermal growth factor receptor cell proliferation signaling pathways. Cancers, 9.10.3390/cancers9050052 ↗
3. Conflicting roles of EGFR expression by subtypes in breast cancer
4. Nair, S., Bonner, J.A., and Bredel, M. (2022). EGFR mutations in head and neck squamous cell carcinoma. Int. J. Mol. Sci., 23.10.3390/ijms23073818 ↗
5. Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies10.1002/cbin.11340 ↗
6. Nimotuzumab: Beyond the EGFR signaling cascade inhibition10.1053/j.seminoncol.2018.04.008 ↗
7. The latest battles between EGFR monoclonal antibodies and resistant tumor cells10.3389/fonc.2020.01249 ↗
8. Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific t cells in head and neck cancer patients10.3389/fphar.2017.00382 ↗
9. Antibodies directed against receptor tyrosine kinases: Current and future strategies to fight cancer10.4161/mabs.29089 ↗
10. EGFR inhibition is effective against KRAS-wild-type disease10.1038/nrclinonc.2017.119 ↗
11. Lee, C.M., and Tannock, I.F. (2010). The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer, 10.10.1186/1471-2407-10-255 ↗
12. Cruz, E., and Veysel, K. (2019). Synthesis and enhanced cellular uptake in vitro of anti-HER2 multifunctional gold nanoparticle. Cancers, 11.10.3390/cancers11060870 ↗
13. Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy10.2217/nnm-2020-0167 ↗
14. Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer10.4161/mabs.3.5.16089 ↗
15. Impact of gold nanoparticles shape on their cytotoxicity against human osteoblast and osteosarcoma in in vitro model. Evaluation of the safety of use and anti-cancer potential10.1007/s10856-019-6221-2 ↗
16. Sengupta, A., Azharuddin, M., Al-Otaibi, N., and Hinkula, J. (2022). Efficacy and immune response elicited by gold nanoparticle- based nanovaccines against infectious diseases. Vaccines, 10.10.3390/vaccines10040505 ↗
17. Enhanced dispersion stability of gold nanoparticles by the physisorption of cyclic poly(ethylene glycol)10.1038/s41467-020-19947-8 ↗
18. PEGylated gold nanoparticle conjugated to monoclonal f19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue10.1021/nn800429d ↗
19. Active targeting of gold nanoparticle as cancer therapeutics10.1039/D0CS01121E ↗
20. Bombesin functionalised gold nanoparticle show in vitro and in vivo cancer receptor specificity10.1073/pnas.1002143107 ↗
21. Gold Nanoparticle as a Vaccine Platform: Influence of Size and Shape on Immunological Responses in Vitro and in Vivo10.1021/nn3057005 ↗
22. Features of thiolated ligands promoting resistance to ligand exchange in self-assembled monolayers on gold nanoparticle10.1071/CH11432 ↗
23. Understanding aggregation-based assays: Nature of protein corona and number of epitopes on antigen matters10.1039/C4RA12089B ↗
24. Insights into the potential of picoplanktonic marine cyanobacteria strains for cancer therapies—Cytotoxic mechanisms against the RKO colon cancer cell line10.1016/j.toxicon.2016.05.016 ↗
25. Oltolina, F., Colangelo, D., Miletto, I., Clemente, N., Miola, M., Verné, E., Prat, M., and Follenzi, A. (2019). Tumor targeting by monoclonal antibody functionalised magnetic nanoparticle. Nanomaterials, 9.10.3390/nano9111575 ↗
26. Synthesis, and characterization of gold nanoparticle as a sensing tool for the lateral flow immunoassay development10.1016/j.sintl.2020.100051 ↗
27. Facile one-pot synthesis of gold nanoparticle using tannic acid and its application in catalysis10.1016/j.physe.2012.04.022 ↗
28. The role of tannic acid and sodium citrate in the synthesis of silver nanoparticle10.1007/s11051-017-3973-9 ↗
29. Hermanson, G. (2013). Bioconjugate Techniques, Elsevier.
30. Cellular uptake of gold nanoparticle triggered by host-guest interactions10.1021/jacs.7b12505 ↗
31. Biomimetic virus-like and charge reversible nanoparticle to sequentially overcome mucus and epithelial barriers for oral insulin delivery10.1021/acsami.7b16524 ↗
32. Nanoparticle uptake: The phagocyte problem10.1016/j.nantod.2015.06.006 ↗
33. Conjugation of polymer-coated gold nanoparticle with antibodies—Synthesis and characterization10.3390/nano5031297 ↗
34. Characterizing the Surface Coverage of Protein–Gold Nanoparticle Bioconjugates10.1021/acs.bioconjchem.8b00366 ↗
35. Facile preparation of albumin-stabilized gold nanostars for the targeted photothermal ablation of cancer cells10.1039/C5TB00633C ↗
36. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery10.1016/j.addr.2015.09.012 ↗
37. One-phase synthesis of water-soluble gold nanoparticle with control over the size and surface functionalities10.1021/la904438s ↗
38. Correlation between surface morphology and surface forces of protein A adsorbed on mica10.1016/S0006-3495(98)77803-8 ↗
39. Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation and biomolecular binding studies10.1021/ac901822w ↗
40. Determination of size and concentration of gold nanoparticle from UV−Vis spectra10.1021/ac0702084 ↗
41. Infrared spectroscopy of proteins10.1016/j.bbabio.2007.06.004 ↗
42. Aldewachi, H., Woodroofe, N., and Gardiner, P. (2018). Study of the stability of functionalised gold nanoparticle for the colorimetric detection of dipeptidyl peptidase iv. Appl. Sci., 8.10.3390/app8122589 ↗
43. Designing novel nano-immunoassays: Antibody orientation versus sensitivity10.1088/0022-3727/43/47/474012 ↗
44. Antibody orientation enhanced by selective polymer–protein noncovalent interactions10.1007/s00216-008-2567-x ↗
45. Nimotuzumab: A novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity10.1517/14712590903110709 ↗
46. Bivalent binding by the intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile10.4161/cbt.11.4.14097 ↗
47. Satyanarayanajois, S.D. (2011). Drug Design and Discovery: Methods and Protocols, Humana Press.10.1007/978-1-61779-012-6 ↗
48. Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of 177Lu-Nimotuzumab10.1080/09553002.2020.1793012 ↗
49. Cisplatin bioconjugated enzymatic GNPs amplify the effect of cisplatin with acquiescence10.1038/s41598-019-50215-y ↗
50. Revisiting metallodrugs for the treatment of skin cancers10.1016/j.ccr.2022.214506 ↗
51. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors10.1186/s13046-021-02039-w ↗
52. Toxicity, and cellular uptake of gold nanoparticle: What we have learned so far?10.1007/s11051-010-9911-8 ↗
53. Biological characterization of cetuximab-conjugated gold nanoparticle in a tumor animal model10.1088/0957-4484/25/29/295102 ↗
54. El Hallal, R., Lyu, N., and Wang, Y. (2021). Effect of cetuximab-conjugated gold nanoparticle on the cytotoxicity and phenotypic evolution of colorectal cancer cells. Molecules, 26.10.3390/molecules26030567 ↗
55. Cytotoxicity-related bioeffects induced by nanoparticle: The role of surface chemistry10.3389/fbioe.2019.00414 ↗